mTOR Inhibition by Drug-Coated Balloon: A Thor's Hammer Against Atherosclerosis?

JACC Cardiovasc Interv. 2024 Jul 8;17(13):1557-1558. doi: 10.1016/j.jcin.2024.04.040. Epub 2024 Jun 5.

Authors

Bernardo Cortese¹, Mehdi H Shishehbor²

Affiliations

¹ Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy; DCB Academy, Milano, Italy. Electronic address: [email protected].
² University Hospitals Harrington Heart and Vascular Institute, Cleveland, Ohio, USA.

PMID: 38842999
DOI: 10.1016/j.jcin.2024.04.040

No abstract available

Keywords: DCB; drug-coated balloons; paclitaxel; sirolimus.

Publication types

Editorial

MeSH terms

Angioplasty, Balloon, Coronary* / adverse effects
Angioplasty, Balloon, Coronary* / instrumentation
Animals
Cardiac Catheters
Cardiovascular Agents / administration & dosage
Coated Materials, Biocompatible*
Coronary Artery Disease / diagnostic imaging
Coronary Artery Disease / therapy
Equipment Design
Humans
Risk Factors
TOR Serine-Threonine Kinases* / antagonists & inhibitors
TOR Serine-Threonine Kinases* / metabolism
Treatment Outcome

Substances

TOR Serine-Threonine Kinases
Coated Materials, Biocompatible
MTOR protein, human
Cardiovascular Agents